Skip to main content
Download PDF

Profiling of the germline mutation BRCA1: p.Ile1845fs in a large cohort of Han Chinese breast cancer

Hereditas volume 157, Article number: 1 (2020) Cite this article

Abstract

Background

Breast cancer is a one of the malignant carcinomas partially caused by genetic risk factors. Germline BRCA1 gene mutations are reportedly associated with breast cancers. Identification of BRCA1 mutations greatly improves the preventive strategies and management of breast cancer. The aim of our study was to investigate the frequency of the deleterious BRCA1: p.Ile1845fs variant in breast carcinomas, as well as the correlation between p.Ile1845fs variant with clinicopathological parameters and clinical outcomes.

Results

A total of 23,481 clinically high-risk patients with breast cancer and 6489 healthy controls were recruited for p.Ile1845fs variant sequencing (either sanger or next generation sequencing). We identified 94 breast cancer patients (0.40%, 94/23481) as well as 11 healthy controls (0.17%, 11/6489) carried p.Ile1845fs variant. BRCA1: p.Ile1845fs variant showed a higher frequency in patients with TNBC molecular typing (20.21%, 19/94) and family history (37.23%, 35/94) compared with non-carriers (P = 3.62E-6 and 0.034, respectively). According to our data, we advanced the frequency of p.Ile1845fs variant and we confirmed that BRCA1: p.Ile1845fs variant was associated with increased risk of breast cancer (OR = 2.36, 95%CI = 1.26–4.89, P = 0.004).

Conclusions

BRCA1: p.Ile1845fs variant was a frequently pathogenic mutation in breast cancer in Han Chinese women and our data may be helpful for diagnosis and therapy of breast cancer.

Background

Breast cancer is a leading health concern among women worldwide, with approximately 252,710 women newly diagnosed cases occurring every year in the world [1, 2]. In the past few years, the rates of mortality have decreased as a result of recent advancements in the understanding of breast cancer biology. However, breast cancer still keeps up with the leading cause of death in women and metastases at distant sites are still responsible for majority of the cancer death [3]. The genetic architecture of breast cancer involves germline pathogenic variants in high and moderate-risk genes, including BRCA1 and BRCA2. Breast cancers is the most frequent cancer in BRCA1/2 pathogenic variant carriers. Recently, studies showed BRCA1 and BRCA2 pathogenic variants carriers have a 72 and 69% cumulative risk up to age 80, respectively [4, 5]. Therefore, identifying more prognostic markers is required to screen high risk patients and it is significant for the development of effective therapeutic strategies.

Breast cancer susceptibility gene 1 (BRCA1) is a large gene with 23 exons located on chromosome 17q12.21. It plays as a tumor suppressor that is essential for maintenance of genome stability and DNA repair [6]. The most common mutation types of BRCA1 are small insertion/deletion frameshift, nonsynonymous truncation, and splice-site alterations [7, 8]. Breast cancer risk based on BRCA1 mutation carrier status will be greatly increased. Understanding the mutational spectra of BRCA1 gene will help carriers to personalize the prevention strategies, including prophylactic mastectomy and salpingo-oopherectomy [9, 10]. The genetic testing for these mutations would directly affect the decisions of carriers and their family members.

In sporadic breast cancer, the frequency and relevance of BRCA1: p.Ile1845fs variant has not been elucidated completely. Therefore, we decided that a comprehensive investigation would be useful to clarify this mutation profiling and prognostic significance in sporadic breast cancer in Han Chinese. In the present study, the frequency of BRCA1: p.Ile1845fs mutation and the relationship between the mutation, clinicopathological parameters and clinical outcomes were evaluated.

Material and methods

A total of 23,481 clinically high-risk breast cancer patients and 6489 healthy controls were recruited at 19 clinical centers in 11 Chinese provinces between 2012 to 2018. Clinicopathological features of the patients, including age, ethnicity, menopausal status, type of tumor, disease stage, lymph nodes and tumor size, were collected. Family history is defined that the breast cancer patients had one or more cancer patients (any kind of cancer) in the first-, second-, or third-degree relatives. The control subjects were hospital-based unrelated healthy individuals with no breast cancer or any other cancers. The written informed consents were signed by all participants. The study protocol was approved by the Ethics Committee of all the hospitals involved.

Genomic DNA was extracted from blood specimens using the QIAamp DNA kit (Qiagen). DNA were amplified by multiplex-amplicon PCR and libraries were then prepared using protocols recommended by Illumina. The validated DNA libraries were sequenced on an Illumina sequencing system (Illumina HiSeq X10). Read pairs (fastq data) generated from the sequencing system were aligned with reference sequences (BRCA1: NM_007300.3) and processed for variant calling. The pathogenic variant p.Ile1845fs was validated by sanger sequencing, and we successfully validated the mutation results with 100% concordance.

The statistical analysis were performed using the R program (http://www.r-project.org/). Chi Square test or the Fisher exact test were used to analyze the two-group comparisons and the OR and the corresponding 95% CI were estimated. All data were presented as the mean ± standard deviation (SD). P-values < 0.05 were considered statistically significant.

Results

We analyzed the BRCA1 pathogenic variant, p.Ile1845fs, with breast cancer risk in 23,481 invasive breast cancer cases (46.24 ± 20.11 years) and age-matched 6489 controls (47.33 ± 13.46 years). A total of 94 p.Ile1845fs mutations were identified in 23,481 (0.40%) unselected breast cancer patients and 11 unaffected controls carried p.Ile1845fs mutation (0.17%, 11/6489). In the overall analysis, BRCA1: p.Ile1845fs variant showed a higher frequency in breast cancer cases (0.40%) than in controls (0.17%) with a greater than two-fold increased breast cancer risk (OR = 2.44, 95% CI = 1.12–5.34, P = 0.034, Table 1).

Table 1 BRCA1: p.Ile1845fs variant in unselected breast cancer cases and controls
Full size table

We summarized the clinicopathogical characteristics of the 94 patients with BRCA1: p.Ile1845fs variant and 23,387 non-carriers in Table 2. The mean age of these breast cancer patients was 46.16 years (sd = 9.80). The mean age of these non-carriers was 46.25 years (sd = 15.52). Among the 94 BRCA1: p.Ile1845fs variant carriers, 44 (46.81%) patients were diagnosed with estrogen receptor (ER) negative status. 46 (48.94%) patients were detected with progesterone receptor (PR) negative status. 35 (37.23%) patients presented with human epidermal growth factor receptor-2 (HER-2) negative status. 6 (6.38%) patients were classified with Luminal-A molecular typing. 26 (27.66%) patients were classified with Luminal-B molecular typing. 12 (12.77%) patients were classified with HER2 overexpression molecular typing. 19 (20.21%) patients were classified with TNBC (Triple-negative breast cancer) molecular typing. 35 (37.23%) patients had family history. TNBC molecular typing was more frequent in mutation carriers compared with non-carriers (P = 3.62E-6). BRCA1: p.Ile1845fs variant carriers were more likely to have family history of cancer (P = 0.034).

Table 2 Clinical characteristics of BRCA1: p.Ile1845fs variant carriers and non-carriers in this study
Full size table

Discussion

In this study we investigated the profiling of the BRCA1: p.Ile1845fs variant in Han Chinese breast cancer. We conducted gene sequencing studies in 23,481 unselected breast cancer cases and 6489 controls and confirmed that BRCA1: p.Ile1845fs variant was associated with increased risk of breast cancer (OR = 2.36, 95%CI = 1.26–4.89, P = 0.004).

BRCA1 is a key factor in the DNA double-strand break repair of other genes that induce human cancers [11, 12]. It plays crucial roles in chromatin remodeling, cell-cycle regulation, and activating DNA repair in response to cellular stress [13, 14]. BRCA1 encodes a 1884-amino-acid-long nuclear protein (NP_009231.2) and is expressed in various tissues including breast tissues. There are more than 1600 known variants in BRCA1 and its pathogenic variants increase the risks of breast cancer [15, 16]. Our genetic data suggested that BRCA1: p.Ile1845fs was a risk factor for breast cancer with statistically significant OR of 2.36.

Clinicopathological characteristics of BRCA1: p.Ile1845fs variant showed 44 (46.81%) patients were diagnosed with ER negative status, 46 (48.94%) with PR negative status and 35 (37.23%) with HER2 negative status. Based on estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER-2) status, we found 6 (6.38%) Luminal-A molecular typing patients and 26 (27.66%) Luminal-B molecular typing patients. Luminal A and Luminal B share similarities in prognosis, while Luminal B have lower expression of hormone receptors, higher expression of proliferation markers, and higher histologic grade than luminal A [17, 18]. Triple-negative breast cancer is defined by aggressive clinical behavior and occurs in 10–15% of sporadic breast cancers [19, 20]. There were 19 (20.21%) TNBC molecular typing patients carried p.Ile1845fs variant. Family history of breast or ovarian cancer is a high risk factor for breast cancer and genetic testing is recommend for these patients [21]. Among total 94 BRCA1: p.Ile1845fs variant carriers, 35 (37.23%) patients had family history.

Recently, more studies focus on effective detection of informative biomarkers for advanced development of early diagnosis and appropriate treatment in breast cancer. Arason A et al. showed the profiling of BRCA1 c.4096 + 3A > G and found 8 heterozygous carriers (0.44%) in 1820 unselected breast cancer cases, and 3 (0.15%) in 1968 healthy controls [22]. BRCA1: p.Val1833Met variant was genotyped among 3531 breast cancer patients and 1558 healthy controls using sanger and next generation sequencing, with 27 (0.77%, 27/3531) carriers in cases while no carriers in controls [23]. Our study accord with a pathogenic BRCA1 mutation: p.Ile1845fs and identified 94 carriers (0.40%) in 23,481 breast cancer patients, and 11 (0.17%, 11/6489) in controls. Our findings add to the current knowledge of BRCA1, which will be of use in clinical genetic counselling.

In summary, we described the frequency of BRCA1: p.Ile1845fs mutation and its clinical aspects in our cohort. We have found that BRCA1: p.Ile1845fs variant is associated with risk of breast cancer. Further genetic studies and meta-analyses are warranted to derive more precise risk estimates for BRCA1: p.Ile1845fs variant. And such carriers should be counselled accordingly, with clinical recommendations and personalized risk-reductionprimary and secondary cancer prevention strategies.

Availability of data and materials

The authors declare that the data supporting the findings of this study are available within the article.

Abbreviations

BRCA1:

Breast cancer susceptibility gene 1

ER:

Estrogen receptor

HER-2:

Human epidermal growth factor receptor-2

PR:

Progesterone receptor

SD:

Standard deviation

TNBC:

Triple-negative breast cancer

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.

    Article  Google Scholar 

  2. Lega IC, Lipscombe LL. Review: diabetes, obesity and Cancer - pathophysiology and clinical implications. Endocr Rev. 2019. Epub ahead of print. PMID: 31722374. https://doi.org/10.1210/endrev/bnz014.

  3. DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A, Jemal A, Siegel RL. Breast cancer statistics, 2019. CA Cancer J Clin. 2019;69(6):438–51.

    Article  Google Scholar 

  4. Mavaddat N, Peock S, Frost D, Ellis S, Platte R, Fineberg E, Evans DG, Izatt L, Eeles RA, Adlard J, et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst. 2013;105(11):812–22.

    Article  CAS  Google Scholar 

  5. Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, Jervis S, van Leeuwen FE, Milne RL, Andrieu N, et al. Risks of breast, ovarian, and contralateral breast Cancer for BRCA1 and BRCA2 mutation carriers. Jama. 2017;317(23):2402–16.

    Article  CAS  Google Scholar 

  6. SK S, Swamy SN, Premalatha CS, Pallavi VR, Gawari R. Aberrant promoter Hypermethylation of RASSF1a and BRCA1 in circulating cell-free tumor DNA serves as a biomarker of ovarian carcinoma. Asian Pac J Cancer Prev. 2019;20(10):3001–5.

    Article  Google Scholar 

  7. Walsh T, Casadei S, Coats KH, Swisher E, Stray SM, Higgins J, Roach KC, Mandell J, Lee MK, Ciernikova S, et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. Jama. 2006;295(12):1379–88.

    Article  CAS  Google Scholar 

  8. Kwong A, Chen J, Shin VY, Ho JC, Law FB, Au CH, Chan TL, Ma ES, Ford JM. The importance of analysis of long-range rearrangement of BRCA1 and BRCA2 in genetic diagnosis of familial breast cancer. Cancer genetics. 2015;208(9):448–54.

    Article  CAS  Google Scholar 

  9. Meijers-Heijboer H, van Geel B, van Putten WL, Henzen-Logmans SC, Seynaeve C, Menke-Pluymers MB, Bartels CC, Verhoog LC, van den Ouweland AM, Niermeijer MF, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2001;345(3):159–64.

    Article  CAS  Google Scholar 

  10. Kwong A, Shin VY, Ho JC, Kang E, Nakamura S, Teo SH, Lee AS, Sng JH, Ginsburg OM, Kurian AW, et al. Comprehensive spectrum of BRCA1 and BRCA2 deleterious mutations in breast cancer in Asian countries. J Med Genet. 2016;53(1):15–23.

    Article  CAS  Google Scholar 

  11. Daza-Martin M, Densham RM, Morris JR. BRCA1-BARD1: the importance of being in shape. Mol Cell Oncol. 2019;6(6):e1656500.

    Article  Google Scholar 

  12. Bose M, Sachsenweger J, Laurila N, Parplys AC, Willmann J, Jungwirth J, Groth M, Rapakko K, Nieminen P, Friedl TWP, et al. BRCA1 mislocalization leads to aberrant DNA damage response in heterozygous ABRAXAS1 mutation carrier cells. Hum Mol Genet. 2019. Epub ahead of print. PMID: 31630195. https://doi.org/10.1093/hmg/ddz252.

  13. Wu Q, Paul A, Su D, Mehmood S, Foo TK, Ochi T, Bunting EL, Xia B, Robinson CV, Wang B, et al. Structure of BRCA1-BRCT/Abraxas complex reveals phosphorylation-dependent BRCT dimerization at DNA damage sites. Mol Cell. 2016;61(3):434–48.

    Article  CAS  Google Scholar 

  14. Kurdekar V, Giridharan S, Subbarao J, Nijaguna MB, Periasamy J, Boggaram S, Shivange AV, Sadasivam G, Padigaru M, Potluri V, et al. Structure-guided synthesis and evaluation of small-molecule inhibitors targeting protein-protein interactions of BRCA1 tBRCT domain. ChemMedChem. 2019;14(18):1620–32.

    Article  CAS  Google Scholar 

  15. Petrucelli N, Daly MB, Feldman GL. Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2. Genet Med. 2010;12(5):245–59.

    Article  CAS  Google Scholar 

  16. Lee A, Moon BI, Kim TH. BRCA1/BRCA2 pathogenic variant breast Cancer: treatment and prevention strategies. Ann Lab Med. 2020;40(2):114–21.

    Article  Google Scholar 

  17. Tran B, Bedard PL. Luminal-B breast cancer and novel therapeutic targets. Breast Cancer Res. 2011;13(6):221.

    Article  CAS  Google Scholar 

  18. Ades F, Zardavas D, Bozovic-Spasojevic I, Pugliano L, Fumagalli D, de Azambuja E, Viale G, Sotiriou C, Piccart M. Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. J Clin Oncol. 2014;32(25):2794–803.

    Article  Google Scholar 

  19. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15 Pt 1):4429–34.

    Article  Google Scholar 

  20. Zurlo G, Liu X, Takada M, Fan C, Simon JM, Ptacek TS, Rodriguez J, von Kriegsheim A, Liu J, Locasale JW, et al. Prolyl hydroxylase substrate adenylosuccinate lyase is an oncogenic driver in triple negative breast cancer. Nat Commun. 2019;10(1):5177.

    Article  Google Scholar 

  21. Runowicz CD, Leach CR, Henry NL, Henry KS, Mackey HT, Cowens-Alvarado RL, Cannady RS, Pratt-Chapman ML, Edge SB, Jacobs LA, et al. American Cancer Society/American Society of Clinical Oncology breast Cancer survivorship care guideline. J Clin Oncol. 2016;34(6):611–35.

    Article  CAS  Google Scholar 

  22. Arason A, Agnarsson BA, Johannesdottir G, Johannsson OT, Hilmarsdottir B, Reynisdottir I, Barkardottir RB. The BRCA1 c.4096+3A>G Variant Displays Classical Characteristics of Pathogenic BRCA1 Mutations in Hereditary Breast and Ovarian Cancers, But Still Allows Homozygous Viability. Genes. 2019;10(11). PMID: 31683985. https://doi.org/10.3390/genes10110882.

    Article  CAS  Google Scholar 

  23. Papamentzelopoulou M, Apostolou P, Fostira F, Dimitrakakis C, Loutradis D, Fountzilas G, Yannoukakos D, Konstantopoulou I. Prevalence and founder effect of the BRCA1 p.(Val1833Met) variant in the Greek population, with further evidence for pathogenicity and risk modification. Cancer Genet. 2019;237:90–6.

    Article  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported by AITA medical research institute. We thank Professor Liu Yun for his English language editing. We are grateful to all the medical institutions in China and the medical association for providing us with cancer incidence data.

Funding

This work was supported by grants from AITA medical research institute.

Author information

Authors and Affiliations

  1. State Key Laboratory of Genetic Engineering and Collaborative Innovation Center for Genetics and Department, School of Life Science, Fudan University, Shanghai, 200436, People’s Republic of China

    Yu Wu

  2. Department of Biostatistics and Computational Biology, School of Life Sciences, Fudan University, Shanghai, 200436, People’s Republic of China

    Yu Wu

  3. AITA medical research institute, Shanghai, 200000, People’s Republic of China

    Huanhuan Zhang, Xiaoling Weng & Honglian Wang

  4. Department of Breast Surgery, Fudan University Shanghai Cancer Center, 270 Dongan Road, Xuhui, Shanghai, 200032, China

    Xiaoling Weng & Zhen Hu

  5. Department of surgery, Luwan Branch of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    Qinghua Zhou, Ying Wu & Yi Shen

Authors
  1. Yu Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Huanhuan Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xiaoling Weng
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Honglian Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Qinghua Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ying Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yi Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Zhen Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

HZ conceived and designed the experiments. WY, ZH, WX and WH performed the mutation analysis and validation. ZQ, WY and SY gathered patients’ data. WY wrote the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Zhen Hu.

Ethics declarations

Ethics approval and consent to participate

All patients had been signed on the consent form.

Consent for publication

Written informed consents were obtained from patients for publication of their individual details and accompanying images in this manuscript.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wu, Y., Zhang, H., Weng, X. et al. Profiling of the germline mutation BRCA1: p.Ile1845fs in a large cohort of Han Chinese breast cancer. Hereditas 157, 1 (2020). https://doi.org/10.1186/s41065-019-0115-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s41065-019-0115-7

Keywords

Hereditas

ISSN: 1601-5223

Contact us